Health China

View Profile


Speaking/Presenting-Abstract/Poster at Mtg

Topic Authors / presenters Event name Event date
1. Reading the literature on clinical trials with a critical eye: recognizing and learning from the mistakes of others. Hue, Viet Nam. Hue, Viet Nam. Talks to 5th Year Medical Students (2 classes) December, 2014
2. i) Systemic treatment for bladder cancer and kidney cancer; ii) Overview of design and interpretation of clinical trials. Hue, Viet Nam. Hue, Viet Nam Talks to Oncologists December, 2014
3. Research Design and Methodology, Part 1: Drug Development; Research Design and Methodology, Part 2: Other types of clinical research ASCO. United States December, 2014
4. Systemic treatment of prostate cancer National Cancer Institute. Hanoi, Viet Nam November, 2014
5. Systemic treatment for non-metastatic and metastatic breast cancer National Cancer Institute. Hanoi, Viet Nam November, 2014
6. Will personalized medicine lead to major improvements in outcome for people with cancer? - a skeptic’s view of the evidence National Cancer Institute of Singapore. Singapore. November, 2014
7. Drug resistance and the microenvironment: strategies to improve the clinical benefit from chemotherapy Institute of Biotechnology and Engineering. Singapore November, 2014
8. How are we going to treat castrate resistant prostate cancer in 10 years? Asia-Pacific GI and Prostate Cancer Meeting, Suntec Centre. Singapore November, 2014
9. Will personalized medicine lead to major improvements in outcome for people with cancer? - a skeptic’s view of the evidence National Cancer Centre. Singapore November, 2014
10. Humphrey Oei Distinguished Lecture: Whither (or wither) the Randomized Controlled Trial? National Cancer Centre. Singapore November, 2014
11. Public Forum: Many clinical trials make claims for benefits from new treatments for cancer: How should we evaluate their validity? National Cancer Centre. Singapore November, 2014
12. i) Systemic treatment for bladder cancer and treatment for metastatic kidney cancer; ii) Overview of design and interpretation of clinical trials National Cancer Institute. Hanoi, Viet Nam November, 2014
13. Whither (or wither) the Randomized Controlled Trial? pan-Canadian Oncology Drug Review Expert Review Committee. Toronto, Ontario, Canada October, 2014
14. 2 talks: 1) An overview of systemic therapy for prostate cancer; ii) Why I refuse to know my PSA ASCO-SNOMR Medical Oncology Meeting. Poiana-Brasov, Romania October, 2014
15. Drug resistance and the microenvironment: strategies to improve the clinical benefit from chemotherapy University of Salamanca. Spain October, 2014
16. Improving the design of clinical studies to enhance drug development Lakeridge Cancer Centre. Oshawa, Ontario, Canada October, 2014
17. presentations: i) Should personalised medicine be funding in low and middle-income countries? ii) When to start systemic therapy: indications for initiation of treatment vs watchful waiting; iii) DEBATE: Speaker against the motion: Docetaxel is the standard of care for metastatic prostate cancer patients starting Androgen Deprivation Therapy (ADT) European Society of Medical Oncology (ESMO). Spain September, 2014
18. 4 Talks: i) Clinical Trial Design and Methodology 1; ii) Clinical Trial Design and Methodology 2; iii) Reading the literature on clincial trials with a critical eye: recognizing and learning from the mistakes of others; iv) Publishing your research findings International Clinical Trials Workshop. Cordoba, Argentina September, 2014
19. Molecular Oncology Weekend for Canadian Residents Medical Oncology. Ontario, Canada July, 2014
20. Pathways to Success in Clinical Research 10th Central European Oncology Congress Best of ASCO meeting. Opatija, Croatia June, 2014
21. Best of ASCO 2014 Genitourinary Tumours 10th Central European Oncology Congress Best of ASCO meeting. Opatija, Croatia. June, 2014
22. Whither? (or Wither?) the Randomised Control Trial Tannock, IF DMOH Grant Rounds, Princess Margaret Cancer Centre. Toronto, Ontario, Canada. June, 2014
23. Post-Plenary Discussion on Prostate Cancer. ASCO Annual meeting. Chicago, United States. May, 2014
24. Whither? (or Wither?) the Randomized Controlled Trial” 2014 Crosbie Lecture National Cancer Institute of Canada (NCIC). Toronto, Canada May, 2014
25. Reading the literature with a critical eye Recognizing and learning from the mistakes of others. Turkish Medical Oncology Society. Antalya, Turkey March, 2014
26. Advances in systemic treatment for prostate cancer Turkish Medical Oncology Society. March, 2014
27. Debate: Will precision Medicine Double the Overall Cancer Cure? Tannock IF, Krzyzanowska M, Moore MJ, Neel B; Moderator: Bristow R Beyond the Genetic Prescription Pad: Personalizing Cancer Medicine in 2014. Toronto, Ontario, Canada. February, 2014
28. Teaching Session with Residents & Fellows. 15th Annual Practical Applications New Agents in Oncology Conference The Institute for Drug Development. San Antonio, Texas, United States February, 2014
29. Exciting news for prostate cancer 15th Annual Practical Applications New Agents in Oncology Conference. The Institute for Drug Development. San Antonio, Texas, United States February, 2014
30. Reading the literature on clinical trials with a critical eye: Recognizing and learning from the mistakes of others; 2. Publishing and presenting your data; 3. Early Stages of a project: Deciding the project, objectives, draft writing, funding; 4. Clinical Trial Design & Methodology: Abstract discussion; 5. Selecting a multi-site clinical trial to active: Part 1 Implementation feasibility and Financial feasibility International Clinical Trial Workshop (ICTW). Santiago, Chile. Presenter(s): # 4 & 5 with Dr. Christina Davies November, 2013
31. Advances in systemic therapy for prostate cancer MOT Congress of the Hungarian Oncological Society. Hungary November, 2013
32. Debate: This house believes that Progression-Free Survival is an appropriate endpoint for drug development (opposing). ECCO. Amsterdam, Netherlands September, 2013
33. Training Program, University of Toronto. Toronto, Ontario, Canada Castrate Refractory Prostate Cancer July, 2013
34. Oral Abstract Session: Double-blind randomized trial of aflibercept vs placebo with docetaxel and prednisone for treatment of metastatic castration-resistant prostate cancer Ian Tannock Genitourinary (Prostate) Cancer. 2013 Annual ASCO meeting. Chicago, Illinois, United States June, 2013
35. 1. Best of ASCO - GU Cancer; 2. Design and Methodology for Phase III trials; 3. Publishing and presenting the results of your trial ICTW and Croatian Society of Oncology. Opatija, Croatia June, 2013
36. Quality of Life Endpoints in Clinical Trials and their Application to Trials of Systemic Therapy for Prostate Cancer NA June, 2013
37. Educational Session: A critical approach to journal articles and presentations: Why you shouldn’t believe everything you read (eQ&A).
 Ian Tannock ASCO/ASH Joint Session. 2013 Annual ASCO meeting. Chicago, Illinois, United States. June, 2013
38. 1. How are we going to treat castration-resistant prostate cancer in 10 years? 2. Reading the literature with a critical eye: recognizing and learning from the mistakes of others. 3. XIX Zjazd Polskiego Towarzystwa Chirurgii Oncologicznej Ian Tannock Gdansk, Poland. May, 2013
39. James Lepoch Symposium: Drug Resistance and the Tumour Microenvironment Medical Biophysics, Medical Sciences Bldg, University of Toronto. Toronto, Ontario, Canada May, 2013
40. Reading the literature with a critical eye: Recognizing and learning from the mistakes of others. DMOH, Princess Margaret Cancer Centre, UHN. Toronto, Canada March, 2013
41. Drug resistance and the tumour micronenvironment: potential of proton pump inhibitors to increase the clinical benefit of chemotherapy DMOH, Princess Margaret Cancer Centre. Toronto, Ontario, Canada. January, 2013
42. Randomized clinical trials. Hematology Oncology Training Program University of Toronto. Toronto, Ontario, Canada January, 2013
43. Effectiveness or cost-effectiveness as the criterion for adopting new cancer treatments? III Kongres Onkologii Polskiej (3rd Congress of Polish Oncology). Warsaw, Poland October, 2012
44. 1.“Can neoadjuvant breast cancer data be used to accelerate drug approval? 2.Highlights in prostate cancer ESMO. Vienna, Austria. Recipient of ESMO Award. October, 2012
45. Meet the Professor: Symposium 1: Effectiveness or Cost-effectiveness as the criteria for introducing new treatments for cancer: Which endpoints should be used to define them? Pfizer. Pearl River, New York, United States September, 2012
46. Cost of new agents in relation to their effectiveness UICC. Montreal, Quebec, Canada. August, 2012
47. Meet the Professor: Symposium 1: Effectiveness or Cost-effectiveness as the criteria for introducing new treatments for cancer: Which endpoints should be used to define them? 3. Best of ASCO: Genitourinary Cancer. Targeting Cancer from Diagnosis to Cure, 3 Talks - Symposium 1 & 2
Meet the Professor Session. Annual Scientific Meeting of Medical Oncology of Australia (MOGA). Brisbane, Australia. August, 2012
48. What matters in the treatment of prostate cancer? Ian Tannock 18th International Oncology Meeting. Salzburg, Austria. July, 2012
49. Niagara-on-the-Lake MOBS July, 2012
50. Is it possible to reduce the risk of prostate cancer? Juravanski Cancer Centre. Hamilton, Ontario, Canada. June, 2012
51. Drug resistance and the tumour microenvironment: Potential of Proton pump inhibitors to increase the clinical benefits to chemotherapy Fred Hutchison Cancer Centre. Seattle, Washington, United States May, 2012
52. Pragmatic issues with large randomized controlled trials Tannock, IF Fellows, DMOH, Princess Margaret Hospital. Toronto, Ontario, Canada. May, 2012
53. Drug resistance and the tumour microenvironment: Potential of proton pump inhibitors to increase the clinical benefit of chemotherapy B.C. Cancer Control Agency. Vancouver, British Columbia, Canada May, 2012
54. Chemo Brain: Breaking the Silence Ontario Medical Association. Toronto, Ontario, Canada. May, 2012
55. Dealing with the industry Fellows, DMOH, Princess Margaret Hospital. Toronto, Ontario, Canada. Fellows’ Teaching Sessions April, 2012
56. 4 talks) 1.When to prescribe neoadjuvant chemotherapy in bladder cancer. 2. Selection of metastatic kidney carcinoma target drugs. 3.Is it possible to reduce the risk of prostate cancer? 4. Hormone Refractory patients New concepts and treatments. 3rd International Symposium of Urological Cancers. Sao Paolo, Brazil April, 2012
57. Cellular basis for drug treatment and mechanisms of resistance Juravanski Cancer Centre. Hamilton, Ontario, Canada. Teaching Seminars to Residents March, 2012
58. Drug resistance and the tumour microenvironment: potential of proton pump inhibitors to increase the clinical benefit of chemotherapy Juravanski Cancer Centre. Hamilton, Ontario, Canada March, 2012
59. Educational Session. 2012 AACR Annual Meeting. Chicago, Illinois, United States. March, 2012
60. Hematology Residents Tannock, IF Princess Margaret Hospital. Toronto, Ontario, Canada. January, 2012
61. Drug resistance and tumour microenvironment: Potential of proton pump inhibitors to increase the clinical benefit of chemotherapy Tannock, IF DMOH Grand Rounds. DMOH, Princess Margaret Hospital. Toronto, Ontario, Canada. January, 2012
62. Lisant la litterature avec un oeil critique: problemes lies a la conception, a l’analyse, a la publication, e a l’interpretation des resultats. 2. Efficacite ou cout-efficacite comme critere pour la registration des nouvelle therapeutiques Tannock, IF Institute Curie. Paris, France November, 2011
63. Drug Resistance and the tumour microenvironment: Potential of proton pump inhibitors to increase the clinical benefit of chemotherapy Tannock, IF Institute of Development Biology and Cancer Research (ISPDC) meeting. Nice, France. November, 2011
64. 1. Cost-effectiveness: relation to clinical importance; 2. Advances in Oncology. 2011 Annual Conference of the German Speaking National Oncology & Hemataology Socieites. Basle, Switzerland October, 2011
65. Cross-Over - the clinician’s perspective 16th ECCO/36th ESMO Multidisciplinary Cancer Congress. Stockholm, Sweden. Special Session in Cross-Over in Trials. September, 2011
66. Partners in Clinical Research & Challenges and success in clinical trials research in EU. Tannock, IF ASCO Advanced Cancer Course in Collaboration with Romanian Society for Radiotherapy and Medical Oncology. Cluj-Napoca, Romania July, 2011
67. Bone protective agents: do they have useful clinical activity and acceptable cost? Tannock, IF Annual ASCO meeting. Chicago, Illinois, United States June, 2011
68. My vision of the future of oncology”
”Highlights of GU Oncology from ASCO 2011 CEOC Annual Meeting. Opatija, Croatia June, 2011
69. ECCLU: What’s new and What’s true in GU Oncology? Tannock, IF The European School of Oncology. Lugano, Switzerland. May, 2011
70. The Frank Ellis Lecture Tannock, IF The UK Radiation Oncology Congress (UKRO), University of Manchester. Manchester, United Kingdom April, 2011
71. Systemic treatment of cancer: problems related to tumour microenvironment and a clinical perspective on drug development Tannock, IF Queen Elizabeth II Health Sciences Centre. Halifax, Nova Scotia, Canada April, 2011
72. Evaluation of Cancer Clinical trials over 3 decades: problems of design, analysis, reporting and interpretation GRAND Rounds Queen Elizabeth II Health Sciences Centre. Halifax, Nova Scotia, Canada. April, 2011
73. 2011 AACR Annual meeting. AACR. Orlando, Florida, United States Tannock, IF The role of phase III trials of targeted therapies: Is the current system viable and are biomarkers the key to survival?”. April, 2011
74. 2011 Annual AACR meeting January, 2011
75. First line cytotoxic treatment in castration resistant prostate cancer: What have we learned in the last twenty years SOGUG Scientific Symposium. Madrid, Spain November, 2010
76. Prostate Cancer: “Why I refuse to have my PSA done” (Mod: Dr. N. Fleshner)

Prostate Cancer: “ADT, metabolic syndrome and bone health: What should urologists know?” 2010 Urology Update. Toronto, Ontario, Canada November, 2010
77. Drug Delivery and Resistance Centre for Continuing Health Professional Education, Faculty of Medicine, McGill University. Montreal, Quebec, Canada. 2nd Quebec Conference on Therapeutic Resistance in Cancer November, 2010
78. Management of advanced disease: new drugs WHO Symposium on Prostate Cancer. Stockholm, Sweden. September, 2010
79. Chemotherapy for castration resistant prostate cancer. Looking beyond docetaxel and mitoxantrone ASCO, Oral Prostate Session. Chicago, Illinois, United States. June, 2010
80. Practical consideration in clinical trial design ASCO, Teaching Lecture/Education Session. Chicago, Illinois, United States. June, 2010
81. Problèmes liés a l’interprétation des résultats des essais cliniques en oncologie, exemple des études d’hormonothérapie adjuvante dans le cancer du sein Institut Curie. Paris, France May, 2010
82. How to improve preclinical evaluation of new treatments to increase their success in clinical trials 3rd Course of in vivo Preclinical Assays in Cancer Therapy, Training Unit, Institut Curie. Paris, France May, 2010
83. Reading the literature with a critical eye: recognizing and learning from the mistakes of others. Meeting. Aviano, Italy. (CANCELLED due to Volcanic Ash/Cancelled flights). ( April, 2010
84. Evaluation of the clinical trial over three decades: problems of design, analysis, reporting and interpretation. Meeting. Gdansk, Poland. (CANCELLED due to Volcanic Ash/Cancelled flights). April, 2010
85. Design of clinical trials to evaluate personalized treatment for cancer Meeting. Poznan, Poland. (Participated by Webcam due to Volcanic Ash/Cancelled flights). April, 2010
86. This house believes that nodal status should no longer dictate adjuvant chemotherapy EBCC-7 European Breast Cancer Conference. Barcelona. DEBATE March, 2010
87. Speaker Against. This house believes that the future of breast cancer prevention is through pharmacological interventions EBCC-7 European Breast Cancer Conference. Barcelona, Spain. March, 2010
88. 1. Management of metastatic renal cell carcinoma: Current Evidence.

2. Integration of surgery and chemotherapy for muscle-invasive bladder cancer

3. Management of metastatic urothelial cancer

4. Management of castration-resistant prostate cancer 2010 Evidence Based Management Conference on Urological Cancers, Tata Memorial Hospital. Mumbai, India. February, 2010
89. L’évolution des essays cliniques en oncologie sur trios décennies: problèmes lies à la conception, à l’inteprétation des résultats Conference. Quebec City, Quebec February, 2010
90. Problems of design, analysis, reporting and interpretation of randomized clinical trials: examples from the cancer literature that are relevant to all branches of medicine. Galen L. Wampler Memorial Lectureship in Oncology, Massey Cancer Center. Richmond, Virginia February, 2010
91. Prostate cancer screening: to be or not to be. Hospital Day Oration Function, Tata Memorial Hospital. Mumbai, India February, 2010
92. Inhibiteurs d’Aromatase: Opinion contre Francophone d’Oncologie Medicale Conference, Séance Oncology Urologique. Lille, France. January, 2010
93. Cancer de la prostate metastatique: nouvelleformes d’hormonotherapie et nouvelles therapeutiques Francophone d’Oncologie Medicale Conference, Séance Oncology Urologique. Lille, France January, 2010
94. Should aromatase inhibitors be considered the standard of care in the treatment of early stage breast cancer 2010 Toronto Breast Cancer Symposium, Systemic Therapy I DEBATE. Toronto, Canada January, 2010
95. Palliative treatment of breast cancer Swedish Breast Cancer Group. Sweden October, 2009
96. 1. Evolution of the cancer clinical trial over three decades: Problems of design, analysis, reporting and interpretation

2. The importance of pragmatic and meaningful outcomes which directly reflect patient benefit in the setting of palliative care. Invited Plenary Talk 2009 British National Cancer Conference. Birmingham, United Kingdom October, 2009
97. Reading the literature with a critical eye: Recognizing and learning from the mistakes of others Grand Rounds, Christie Hosptial. Manchester, United Kingdom October, 2009
98. Drug Resistance in metastatic prostate cancer ECCO 15. Berlin September, 2009
99. Lessons in clinical trials design Annual Meeting, US Oncology Research Team. Dallas, Texas. (Declined due to previous commitment in Vancouver, BC). August, 2009
100. Limited drug distribution and repopulation as neglected causes of drug resistance in solid tumours Cancer Genes: Discovery and Exploitation, 2009 The Institute of Cancer Research Centenary Conference. London, United Kingdom June, 2009
101. Reading the literature with a Critical Eye: Recognizing and learning from the mistakes of others University Clinic Golnik. Golnik, Slovenia June, 2009
102. 1. Pharmacoeconomics in Oncology
2. Update in GU Oncology Central European Oncology Congress. Opatija, Croatia June, 2009
103. CLINICAL TIRALS EDUCATIONAL SESSION: “Practical considerations in the design and interpretation of clinical trials”

ORAL PRESENTATION: “Cognitive function and fatigue in colorectal cancer (CRC) patients: Baseline assessments prior to chemotherapy”

POSTER DISCUSSIONS: 
1. “Absolute benefits of experimental medical therapies in phase III randomized clinical trials (RCTs) for breast and colorectal cancer”

2. “Global drug development in cancer: a cross-sectional study of clinical trial registries”. ASCO. Orlando, Florida, United States May, 2009
104. . Current status of endocrine treatment and chemotherapy in advanced prostate cancer. V Curso Interdisciplinario de Oncologia: Tumores Urologicos, Session on Carcinoma of the Prostate. Oviedo, Spain May, 2009
105. Why I refuse to know my PSA V Curso Interdisciplinario de Oncologia: Tumores Urologicos, Session on Evaluation of PSA as a Diagnostic Test. Oviedo, Spain May, 2009
106. Drug resistance and the solid tumor microenvironment: New Treatment Strategies in Medical Oncology. Il Lección Conmemorativa Clara Campal, Hospital Universitario Madrid Sanchinarro. Madrid, Spain May, 2009
107. Poor drug distribution and repopulation as neglected and modifiable causes of drug resistance in solid tumours Grand Rounds, Roswell Park. Buffalo April, 2009
108. Poor drug distribution and repopulation as neglected and modifiable causes of drug resistance in solid tumours Grand Rounds, Taussig Cancer Institute, Cleveland Clinic. Ohio April, 2009
109. Poor drug distribution and repopulation as neglected and modifiable causes of drug resistance in solid tumours . “New Frontiers” Society for Thermal Medicine 2009. Tuscon, Arizona. April, 2009
110. Complication: Chemo Brain. Palliative Medicine & Supportive Oncology 2009, The 13th Annual International Symposium. Fort Lauderdale, Florida. March 5-6, 2009 March, 2009
111. Late effects of chemotherapy. Palliative Medicine & Supportive Oncology 2009, The 13th Annual International Symposium. Fort Lauderdale, Florida. March 5-6, 2009. March, 2009
112. Chemotherapy: Is it really palliative? Palliative Medicine & Supportive Oncology 2009, The 13th Annual International Symposium. Fort Lauderdale, Florida. March 5-6, 2009. March, 2009
113. Urology Organ Preservation and Newer Options Session
”Systemic Therapy in Prostate”
”Renal Cell Carcinoma

ISO Special Symposiium: “Breast Cancer Trials Clinical Review”

Participant: Consensus Discussion. Biennial Conference of Indian Society of Oncology, Consensus Discussion. India. February, 2009
114. Systemic Therapy in Prostate. Biennial Conference of Indian Society of Oncology, Urology Organ Preservtion and Newer Options Session. India. February 13-19, 2009. February, 2009
115. Renal Cell Carcinoma Biennial Conference of Indian Society of Oncology, Urology Organ Preservtion and Newer Options Session. India. February 13-19, 2009. February, 2009
116. Doit-on être influence par les aspects financiers dans le processus de validation des Recommendations Cliniques? 11th Cours Francophone Supérieur sur le Cancer due Sein Acropolis: Les Muses. Nice, France January, 2009
117. Reading the literature with a critical eye: Evaluating the results of clinical trials. Mediterranean Cancer Congress, Institute of Oncology. Istanbul, Turkey November, 2008
118. Evolution of chemotherapy for hormone refractory prostate cancer The 8th Princess Margaret Hospital Conference, Developments in Cancer Management: Conquering Cancer in our Lifetime, 50th Anniversary, Prostate Cancer October, 2008
119. Cognitive Dysfunction Following Breast Cancer Therapy 10th Annual Lynn Sage Breast Cancer Symposium, Robert H. Lurie Comprehensive Cancer Center. Chicago, Illinois October, 2008
120. . The microenvironment of solid tumours and response to systemic treatment The 8th Princess Margaret Hospital Conference, Developments in Cancer Management: Conquering Cancer in our Lifetime, 50th Anniversary, Keynote Address October, 2008
121. Genitourinary Tumors ESMO Conference, Poster Symposium. Sweden September, 2008
122. Advanced Prostate Cancer: The changing face of hormonal therapy ESMO Conference. Sweden September, 2008
123. Writing up your findings ACORD. Australia August, 2008
124. Highlights in Prostate Cancer ESMO Conference. Lugano, Switzerland July, 2008
125. 1. Practical Considerations in the design and evaluation of clinical trials
2.ASCO and conflict of interest: Get tough or stop meddling? Annual ASCO meeting. Chicago, Illinois, United States May, 2008
126. Cognitive impairment associated with chemotherapy for breast cancer: An exploratory case-controlled study. CBCRA Reasons for Hope Conference. Vancouver, British Columbia, Canada. April, 2008
127. Can we afford the future: effectiveness or cost-effectiveness as the criterion for introducing new therapies for breast cancer? Keynote Symposium: 6th European Breast Cancer Conference (EBCC.6), Can we walk away from economics? Berlin, Germany. April, 2008
128. Limited drug penetration and repopulation as important and neglected causes of drug resistance in solid tumours Grand Rounds, Dalhousie University. Halifax, Nova Scotia April, 2008
129. Limited drug penetration and repopulation as important and neglected causes of drug resistance in solid tumours Threshold Pharmaceuticals. San Francisco February, 2008
130. What is needed in the development of a new therapeutic for prostate cancer? Prostate Meeting. Vancouver, Ontario, Canada January, 2008
131. Limited drug distribution and repopulation as important and neglected causes of drug resistance in solid tumours VII Sao Paolo Research Conference, Cancer Today, From Molecular Biology to Treatment. Brazil November, 2007
132. Limited drug distribution and repopulation as important and neglected causes of drug resistance in solid tumors Clinical Centre Grand Rounds, National Cancer Institute. Bethesda. November, 2007
133. Limited drug penetration and repopulation as important and neglected causes of drug resistance in solid tumors. Annual Retreat - Clinical and Translational Research at Manitoba Institute of Cell Biology Retreat. Winnipeg. October, 2007
134. Evidence-based medicine in Oncology (given in French)

The Adjuvant Chemotherapy (given in French). AJORA. Lyon, France. given in FRENCH, “Chimiothérapie Adjuvante”. October, 2007
135. Cancer Based Medicine (GU): “Case-based cancer medicine – Prostate Cancer”. Clinical Challenges in Cancer Medicine 11th Annual Fall Oncology Conference. Hilton Head, South Carolina, United States. September, 2007
136. Innovations in Targeted Therapies (GU): “Targeted therapies in Genitourinary Cancer”. Clinical Challenges in Cancer Medicine 11th Annual Fall Oncology Conference. Hilton Head, South Carolina, United States September, 2007
137. Interpretation and application of clinical trials Clinical Challenges in Cancer Medicine, 11th Annual Fall Oncology Conference, Keynote Lecture. Hilton Head, South Carolina, United States. September, 2007
138. Latest Developments in Prostate Cancer ESMO Conference, Breakout Session. Lugano, Switzerland July, 2007
139. Presentation by an expert speaker ESMO Conference, Highlights in Prostate Cancer. Lugano, Switzerland. July, 2007
140. Reading the literature with a critical eye: Recognizing and learning from the mistakes of others. Institute of Oncology. Lubljana, Slovenia June, 2007
141. rostate Cancer: From adjuvant hormonal therapy to second line chemotherapy ASCO. Chicago, Illinois June, 2007
142. Managing fatigue in cancer patients ASCO. Chicago, Illinois June, 2007
143. Teaching Lecture: Practical considerations in the design of clinical trials
Invited Discussant:
1. Prostate Cancer: From Adjuvant hormonal therpay to second line chemotherapy.
2. Managing fatigue in cancer patients ASCO. Chicago, Illinois, United States. Teaching Lecture June, 2007
144. 1. How to build a successful career in Oncology
2. Update on therapy of genitourinary cancer. Central European Oncology Congress. Opatija, Croatia June, 2007
145. Patient-reported outcomes in clinical practice. ISOQOL Conference. Budapest, Turkey June, 2007
146. Breast Cancer Trials: surrogate endpoints and the hazards of early stopping. Breast Rounds, Princess Margaret Hospital/University Health Network. Toronto, Ontario, Canada March, 2007
147. Limited penetration and repopulation as important and neglected causes of drug resistance in solid tumors Fidler Symposium, M.D. Anderson. Houston, Texas, United States. March, 2007
148. Invited Lecture:
Effects of adjuvant chemotherapy for early breast cancer on neurocognitive functions and fatigue

Teaching Lecture: 
The design, analysis and reporting of trials of adjuvant therapy for breast cancer. Early Breast Cancer, Updated multidisciplinary approach: From screening to treatment International Conference between State of Kuwait and Canada-France-Lebanon-Switzerland. Kuwait, United Arab Emirates. March, 2007
149. Oral Abstract Presentation Session 2007 Prostate Cancer Symposium. Orlando, Florida, United States February, 2007
150. Which choice leads to a life least bothered after Prostate Cancer therapy. 2007 Prostate Cancer Symposium, Session on Health Related Quality of Life. Orlando, Florida, United States February, 2007
151. CLOSING TALK: The future of multidisciplinary oncology Dutch National Multidisciplinary Oncology Conference, Closing Talk. Amsterdam, Netherlands February, 2007
152. Bases conceptuelles et pratiques des essays thérapeutiques dans le cancer de la prostate 15th Journée Scientifique de l’ARTP. Paris, France December, 2006
153. 1. Cancer clinical trials: the key to improving outcome
2. Chemotherpay for advanced prostate cancer
3. Fatigue and cognitive function related to chemotherapy
4. Limited penetration and repopulation as important and neglected causes of drug resistance in solid tumours. XVII Brazilian Congress of Cancer, Brazilian Society of Cancer. Sao Paulo, Brazil November, 2006
154. Debate: There is still a role for immunotherapy in first-line treatment of metastatic kidney cancer. 6th Princess Margaret Hospital Conference. Toronto, Ontario, Canada. October, 2006
155. Faculty and Organizer Cognitive Workshop and IPOS meeting. Venice, Italy. October, 2006
156. Should secondary hormonal treatment be used prior to chemotherapy after progression on first line hormonal treatment? Hot Topics in Uro-Oncology. London, United Kingdom October, 2006
157. How to interpret Clinical Trials. Orientation Week Medical Oncology Training Program, Princess Margaret Hospital. Toronto, Ontario, Canada July, 2006
158. Assessing Palliation in Palliative Trials ASCO 2006, ASCO Fellows’ Symposium. Atlanta, Georgia, United States June, 2006
159. Quality of life of patients with metastatic hormone refractory prostate cancer following treatment with docetaxel or mitoxantrone in the TAX-327 study ASCO 2006. Atlanta, Georgia. with Mr. Pond. June, 2006
160. Association of pain and quality of life response with PSA response and survival of patients with metastatic hormone refractory prostate cancer treated with docetaxel or mitoxantrone in the TAX-327 study. ASCO 2006. Atlanta, Georgia. with Dr. Berthold June, 2006
161. Reading the literature with a critical eye: How to assess the quality and relevance of clinical trials described in ASCO abstracts and in the literature ASCO 2006, MEET THE PROFESSOR. Atlanta, Georgia, United States. June, 2006
162. Methods in Clinical Cancer Research Workshop ASCO/AACR. Flims, Switzerland June, 2006
163. A breast cancer case: your money or your life! Prof. Alan Coates Ceremony, The Cancer Council of Australia, Royal Prince Alfred Hospital, GRAND Rounds. New South Wales, Australia May, 2006
164. Know your PSA: Not always good advice. Prof. Alan Coates Ceremony, The Cancer Council of Australia, Royal Prince Alfred Hospital. New South Wales, Australia. May, 2006
165. Endpoints of clinical trials: Which outcome measures reflect benefit to patients Annual Scientific meeting of CAMO. Montreal, Canada April, 2006
166. Limited drug distribution in tumours and repopulation as important and neglected causes of resistance to anticancer treatment Conference Exceptionnelle, Institut Curie. Paris, France. March, 2006
167. 1. Scientific Session: “Study design in the age of molecular biology”
2. Moderator: “Breast Cancer in the elderly”
3. Europa Donna Workshop Speaker: “The role of the clinician/principal investigator”. 5th European Breast Cancer Conference, Scientific Session: “How should we do phase II/III trials in the age of molecular biology”. Nice, France March, 2006
168. Breast Cancer: From Gene to Cure 5th European Cancer Centre. Amsterdam, Netherlands February, 2006
169. Overview of Combined Modality Approach Symposium on Combined Modality Management of Malignancies of Head, Neck and Chest, Hong Kong Cancer Institute. Hong Kong. Draft Title January, 2006
170. Quality of Life and Symptom control should be primary endpoints in palliative trials. 11th Annual Conference on The Science & Art of Pain and Symptom Management, CME, University of Toronto November, 2005
171. Combined modality treatment with radiation and drugs (chemotherapy and biological agents: when and why does it work? BIR, Combined Chemotherapy and Radiotherapy in Head and Neck Cancer Conference October, 2005
172. Limited drug distribution in tumours and repopulation as important and neglected causes of resistance to anticancer treatment. Overview Talk, Department of Medical Biophysicis Retreat. Geneva Park. October, 2005
173. Chemotherapy-radiotherapy: Any real progress? Physical, Chemical and Biological Targeting in Radiation Oncology 7th International Conference on Dose, Time and Fractionation in Radiation Oncology September, 2005
174. Late-Stage Prostate Cancer Man-to-Man Prostate Cancer Support Group. Toronto, Ontario, Canada. September, 2005
175. Chemotherapy related cognitive dysfunction. Charles L. Moertel Lectureship, Mayo Civic Center. Rochester, New York, United States September, 2005
176. Update on chemotherapy for bladder and prostate cancer New Developments in Cancer Management, The 5th Princess Margaret Hospital Conference. Toronto, Ontario, Canada. September, 2005
177. “Practical tips for oncologists: Reading the literature with a critical eye – how to assess the quality and relevance of clinical trials described at ASCO and in the literature” Meet the Professor Session, ASCO. United States. (given twice). May, 2005
178. Neurosciences Research Symposiium and Crolla Family Brain Tumour Lectureship
Cognition and Cancer
”Impact of chemotherapy on cognitive function” Sunnybrook & Women’s Health Sciences Centre. Toronto, Ontario, Canada May, 2005
179. Mini-course on Clinical Trials AACR Educational Session. Los Angeles, California. April, 2005
180. Tumour physiology as an important and neglected cause of drug resistance AACR Educational Session. Los Angeles, California April, 2005
181. 1. Gray Zones in breast cancer adjuvant therapy.
2. Non-classical causes of drug resistance
3. Response criteria, quality of life and symptom control 16th National Congress of Cancer. Antalya, Turkey. April, 2005
182. Features of a high quality phase 3 trial. AACR Educational Session. Los Angeles, California. April, 2005
183. Drug resistance in solid tumours AACR Educational Session. Los Angeles, California April, 2005
184. Medical treatment for prostate cancer Canadian Prostate Cancer Network. Brampton, Ontario, Canada. March, 2005
185. Hormone therapy and chemotherapy in the treatment of prostate cancer Prostate Cancer Support Group. Newmarket, Ontario, Canada February, 2005
186. Workshop: “Understanding clinical trials”
After Dinner Lecture: “Interpretation of evidence - science, art and prejudices”. EWOC 9. Flims, Switzerland. Workshop. January, 2005
187. Quality of life endpoints in clinical trials and their application to trials of systemic therapy for prostate cancer. Grand Rounds, Barbara Ann Karmanos Cancer Institute. Detroit, Michigan, United States January, 2005
188. Hormone therapy and chemotherapy in the treatment of prostate cancer Man-to-Man Prostate Cancer Support Group. Barrie, Ontario, Canada. November, 2004
189. Drug penetration and repopulation and important (and rather neglected) causes of drug resistance in solid tumours Seminar Series at The Prostate Centre. Vancouver, Ontario, Canada. November, 2004
190. Quality of life and symptom control should be primary endpoints of palliative trials. Pain and Symptom Management Conference. Toronto, Ontario, Canada November, 2004
191. Recognizing good and bad trials ASCO Clinical Trials Workshop. Dallas, Texas, United States. October, 2004
192. Opening Keynote Speaker: “Tumour physiology as an important and neglected cause of clinical drug resistance”
Session 1: “Emerging role of chemotherapy in advanced prostate cancer”. New Developments in Cancer Management, 4th Annual Princess Margaret Hospital Conference, Opening Keynote Lecture. Toronto, Ontario, Canada. September, 2004
193. 1. What’s new in genitourinary malignancies.
2. Is early disclosure of the results of randomized trials of benefit to the patient and to the scientific community ACORD Workshop, Medical Oncology Group of Australia. Queensland, Australia August, 2004
194. 1. Quality of Life and symptom control for patients with hormone-resistant prostate cancer
2. Routine PSA screening for early detection of prostate cancer CME 4th International Prostate Cancer Congress. Bahamas. July, 2004
195. Limited penetration of drugs in tumor tissue and repopulation of surviving tumor cells as important and neglected causes of therapeutic resistance: relevance to targeted therapy. 2004 Molecular Therapeutics of Cancer Gordon Research Conference, Colby-Sawyer College. New London, New Hampshire July, 2004
196. Methods: Reading the Literature with a Critical Eye – How to assess the quality and relevance of clinical trials described in ASCO abstracts and in the literature. 40th ASCO Annual Meeting, Meet the Professor Session. New Orleans, Louisiana. June, 2004
197. Response Evaluation in Oncology 4th Central European Oncology Congress (CEOC). Croatia June, 2004
198. Introducing new systemic treatments in oncology: The Canadian Experience Institute of Oncology Ljubljana. Slovenia June, 2004
199. Impact of chemotherapy on cognitive function. Cognition and Cancer, Neurosciences Research Symposium and Crolla Family Brain Tumour Lectureship, Sunnybrook & Women’s Health Sciences Centre. Toronto, Ontario, Canada May, 2004
200. Cancer of the Great Toe: a critical overview of clinical trials Grand Rounds, Evidence to Support Clinical Trials in Oncology, USC. Long Beach, California May, 2004
201. Fatigue, menopausal symptoms and cognitive dysfunction associated with chemotherapy. Medical Grand Rounds, British Columbia Cancer Control Agency. Vancouver, Ontario, Canada April, 2004
202. Workshop Chair: “Using targeted therapeutics (translational medicine)”
Luncheon Lecturer: “Early dissemination of Clinical Trials results”. Exploring the FUTURE of Breast Disease, 28th Annual Symposium of the American Society of Breast Disease. Boston, Massachusetts, United States April, 2004
203. DEBATE: This house believes that early disclosure of positive results of randomized trials is of benefit to the patient and to the scientific community. 4th European Breast Cancer Conference, EORTC. Hamburg, Germany. Debate March, 2004
204. Lecture and Roundtable Discussions: 
1. “Tumour physiology as an important and neglected cause of drug resistance”
2. “The treatment of metastatic prostate cancer”
3. “Fatigue, menopausal symptoms and cognitive dysfunction associated with chemotherapy”. Update in Oncology”, Scientific Institute San Raffaele University Hospital. Milan, Italy. Lecture and Round Table Discussion March, 2004
205. 1. The true risk/benefit analysis of currently available cancer therapies
2. Impact of chemotherapy drugs on cognition
3. Bone loss from hormonal treatment of prostate cancer. The 2nd Annual Future of Supportive Therapy in Oncology: An International Congress. Saint Kitts And Nevis February, 2004
206. From evidence-based medicine to clinical practice: not always straightforward City Wide Oncology Rounds. Toronto, Ontario, Canada. February, 2004
207. Cognitive function and chemotherapy OISE, University of Toronto. Toronto, Ontario, Canada February, 2004
208. Neurocognitive aspects in tumour therapy Canadian Oncology Society Erythropoietin Cancer Research Conference, The Emerging Role of EPO in Oncology. Toronto, Ontario, Canada. January, 2004
209. Does palliative treatment palliate? The influence of cancer treatment on quality of life for patients with prostate and other cancers Yale Cancer Center Grand Rounds (CME). January, 2004
210. Cancer of the Great Toe: A critical assessment of clinical trials EORTC Data Centre. Brussels. December, 2003
211. . Combined modality treatment with radiation and drugs: When and why does it work?
2. Tumour physiology as an important and neglected cause of drug resistance
3. Cancer of the Great Toe: A critical assessment of clinical trials.
4. Treatment of metastatic prostate cancer.
5. Fatigue, menopausal symptoms and cognitive dysfunction associated with chemotherapy 2nd Emmanuel van der Schueren Guest Professor. Leuven, Belgium. December, 2003
212. The influence of cancer treatment on quality of life and cognitive function Harold Warwick Award Lecture, Medical Sciences Building, University of Toronto. Toronto, Ontario, Canada October, 2003
213. Responding to the Needs of Breast Cancer Survivors: 
”Cognitive Changes Associated with Chemotherapy ‘Chemo-Fog’”. 2003 Life after Breast Cancer Conference, Hamilton Regional Cancer Centre. Hamilton, Ontario, Canada October, 2003
214. Plenary Session: Evaluating the evidence ECCO 12, Plenary Session. Copenhagen, Denmark. September, 2003
215. Tumour physiology as an important and neglected cause of resistance to chemotherapy. Werner-Gren Symposium: “Biology of Tumour Stroma: Potential Avenues in tumour therapy”. Stockholm, Sweden September, 2003
216. Educational Symposium: From Clinical Trials to clinical practice ECCO 12. Copenhagen, Denmark. September, 2003
217. Fatigue, menopausal symptoms and cognitive dysfunction associated with adjuvant chemotherapy for breast cancer 2nd Congress of the World Society of Breast Health. Budapest, Hungary. June, 2003
218. Quality of Cancer Care. Keynote Lecture, ESMO Educational Meeting. Edinburgh, Scotland, United Kingdom. June, 2003
219. Session 4: Prevention and management. “Intervention studies”. 6th World Congress Psycho-Social Oncology. Banff, Alberta, Canada April, 2003
220. Session 1: Cognitive dysfunctio associated with chemotherapy.
”Cognitive dysfunction in relation to fatigue and menopausal symptoms in patients receiving adjuvant chemotherapy” 6th World Congress Psycho-Social Oncology, Session 1: Cognitive dyfunction associated with chemotherapy. Banff, Alberta, Canada April, 2003
221. Welcome and Goals 6th World Congress Psycho-Social Oncology. Banff, Alberta, Canada April, 2003
222. Workshop on Cognitive Dysfunction Associated with Chemotherapy 6th World Congress Psycho-Social Oncology. Banff, Alberta, Canada April, 2003
223. Clinical Trials in Oncology: Pitfalls and Progress ASTRO) The 37th Annual San Francisco Conference Radiation Oncology. San Francisco, California. February, 2003
224. Clinical Trials in Oncology: Pitfalls and Progress The Vaeth Lecture, (ASTRO) The 37th Annual San Francisco Conference Radiation Oncology. San Francisco, California. February, 2003
225. The influence of cancer treatment on quality of life and cognitive function Morton Kligerman Awardee/Lecturer. Philadelphia, Pennsylvania, United States January, 2003



Site wide Speaking/Presenting-Abstract/Poster at Mtg

Presentation Event Month, Year
Improving the efficiency of cancer drug development: the importance of mechanistic translational studies in early clinical trials Asian Oncology Summit 2015 April, 2015
Drug resistance and the tumour microenvironment: inhibition of autophagy as a strategy to improve clinical benefit Asian Oncology Summit 2015 April, 2015
Special Session ASCO Annual Meeting 2013 June, 2013
Program Committee 44th ASCO Annual Meeting February, 2007
ASCO Special Lecture: Diagnosis and Treatment of Men with Prostate Cancer: Can We Afford the Future? 44th ASCO Annual Meeting February, 2007
Oral Abstract Presentation Session C 44th ASCO Annual Meeting February, 2007
General Session IV: Panel Discussion: Debate Issues in Health-Related Quality of Life 44th ASCO Annual Meeting February, 2007

Biotech China 2014
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.